NBIX Stock Summary and Trading Ideas (Neurocrine Biosciences | NASDAQ:NBIX)

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Neurocrine Biosciences trades on the NASDAQ stock market under the symbol NBIX.

As of January 12, 2026, NBIX stock price declined to $132.66 with 1,823,481 million shares trading.

NBIX has a beta of 0.75, meaning it tends to be less sensitive to market movements. NBIX has a correlation of 0.12 to the broad based SPY ETF.

NBIX has a market cap of $13.23 billion. This is considered a Large Cap stock.

Last quarter Neurocrine Biosciences reported $795 million in Revenue and $2.17 earnings per share. This beat revenue expectation by $49 million and exceeded earnings estimates by $.30.

In the last 3 years, NBIX traded as high as $160.18 and as low as $84.23.

The top ETF exchange traded funds that NBIX belongs to (by Net Assets): VTI, IJH, VB, VBK, VXF.

NBIX has underperformed the market in the last year with a price return of -4.4% while the SPY ETF gained +19.2%. NBIX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.2% and -8.7%, respectively, while the SPY returned +3.9% and +0.7%, respectively.

NBIX support price is $132.96 and resistance is $138.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NBIX shares will trade within this expected range on the day.